Published On: 6/11/2024
EASL 2024 Research: Presentation by A. Sidney Barritt IV, MD, MSCR
Lead author and member of the TARGET-NASH steering committee, A. Sidney Barritt IV, MD, MSCR, presented a new Target RWE study analysis at EASL 2024 titled “Real-World Use of Glucagon Like Peptide 1 Receptor Agonist in Patients with MASLD: A Cross-Sectional Analysis from Target NASH.”
The study analyzed the use of GLP-1 receptor agonists in real world patients diagnosed with MASL, metabolic dysfunction-associated steatohepatitis (MASH), and MASLD with cirrhosis – finding that 11% of the adult cohort were prescribe GLP-1 therapy. Watch this video presentation by Dr. Barritt highlighting the important study:
About Target RWE
Target RWE generates real-world evidence (RWE) that informs strategic decisions across the drug development lifecycle. Our unique combination of clinical, analytical and technical expertise enables comprehensive insight generation from complete retrospective and prospective longitudinal patient journeys, with unparalleled scale and accuracy.
Visit our website to learn more: https://targetrwe.com/
Contact:
Kayla Slake
Senior Manager, Marketing
984.234.0268 ext 205
More News
-
11/26/2024
ACG 2024: Target RWE Presents Key MASH and EGIDs Data from Leading Liver Disease & Gastroenterology Real-World Registries -
11/25/2024
New Target RWE Research Validates Updated Liver Disease Terminology in Children -
11/18/2024
Target RWE Unveils Latest Developments in TARGET-Liver Disease and Cirrhosis Quality Collaborative Partnership with the American Association for the Study of Liver Diseases -
10/29/2024
DIA RWE 2024 Research: Presentation by Nuvan Rathnayaka -
10/29/2024
DIA RWE 2024 Research: Presentation by David Pritchard, PhD